Anne E. O’Donnell

4.0k citations

51 papers · 2.0k indexed · 2 hit papers · h-index 19

Impact in

Pulmonary and Respiratory Medicine top 1%
- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Tracheal and airway disorders
- Chronic Obstructive Pulmonary Disease (COPD) Research
Speech and Hearing top 2%
- Dysphagia Assessment and Management

Papers in ⓘ

Pulmonary and Respiratory Medicine 34
- Cystic Fibrosis Research Advances 31
- Tracheal and airway disorders 17
- Neonatal Respiratory Health Research 15
Emergency Medical Services 7
- Pediatric health and respiratory diseases 7

Co-authors: Jonathan Ilowite (2 shared papers)Alan F. Barker (1 shared paper)Robert B. Fick (1 shared paper)Armand Wolff (2 shared papers)Mark L. Metersky (9 shared papers)James D. Chalmers (9 shared papers)Charles L. Daley (7 shared papers)Matthias Salathé (5 shared papers)
Journals: CHEST Journal (11 papers)Clinics in Chest Medicine (4 papers)Journal of Agricultural and Food Chemistry (3 papers)The Lancet Respiratory Medicine (3 papers)European Respiratory Journal (3 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Anne E. O’Donnell

47 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis 2020 · 207 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 New England Journal of Medicine
2016 CHEST Journal

Peers

Countries citing papers authored by Anne E. O’Donnell

Since Specialization

Citations

This map shows the geographic impact of Anne E. O’Donnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne E. O’Donnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne E. O’Donnell more than expected).

Fields of papers citing papers by Anne E. O’Donnell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne E. O’Donnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne E. O’Donnell. The network helps show where Anne E. O’Donnell may publish in the future.

Co-authors

The 25 scholars most cited alongside Anne E. O’Donnell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anne E. O’Donnell Line = papers co-authored together Anne E. O’Donnell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Treatment of Idiopathic Bronchiectasis With Aerosolized Recombinant Human DNase I CHEST Journal ·Anne E. O’Donnell, Alan F. Barker, Jonathan Ilowite, Robert B. Fick	1998	285
2	Adult Patients With Bronchiectasis CHEST Journal ·Timothy R. Aksamit, Anne E. O’Donnell, Alan R. Barker, Kenneth N. Olivier, Kevin Winthrop, M. Leigh Anne Daniels, Margaret M. Johnson, Edward Eden, David E. Griffith, Michael R. Knowles, Mark L. Metersky, Matthias Salathé, Byron Thomashow, Gregory Tino, Gerard Turino, Betsy Carretta, Charles L. Daley Hit paper breakdown →	2016	251
3	Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis New England Journal of Medicine ·James D. Chalmers, Charles Haworth, Mark L. Metersky, Michael R. Loebinger, Francesco Blasi, Oriol Sibila, Anne E. O’Donnell, Eugene J. Sullivan, Kevin C. Mange, Carlos Fernández‐Peña, Jun Zou, Charles L. Daley Hit paper breakdown →	2020	207
4	Bronchiectasis CHEST Journal ·Anne E. O’Donnell	2008	158
5	Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials The Lancet Respiratory Medicine ·Alan F. Barker, Anne E. O’Donnell, Patrick A. Flume, Philip J. Thompson, Jonathan Ruzi, Javier de Gracia, Wim Boersma, Anthony De Soyza, Lixin Shao, Jenny Zhang, Laura Haas, Sandra A. Lewis, Sheila Leitzinger, A. Bruce Montgomery, Matthew McKevitt, David Gossage, Alexandra L. Quittner, Thomas G. O’Riordan	2014	153
6	Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials The Lancet Respiratory Medicine ·Charles Haworth, Diana Bilton, James D. Chalmers, Angela Davis, Juergen Froehlich, Igor Gonda, Bruce Thompson, Adam Wanner, Anne E. O’Donnell	2019	129
7	Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores Thorax ·Alexandra L. Quittner, Anne E. O’Donnell, Matthias Salathé, Sandra A. Lewis, Xiaoming Li, A. Bruce Montgomery, Thomas G. O’Riordan, Alan F. Barker	2014	121
8	Pulmonary Manifestations of HIV Infection in the Era of Highly Active Antiretroviral Therapy CHEST Journal ·Armand Wolff, Anne E. O’Donnell	2001	97
9	Bronchiectasis — A Clinical Review New England Journal of Medicine ·Anne E. O’Donnell	2022	73
10	A Preliminary Quality of Life Questionnaire-Bronchiectasis CHEST Journal ·Alexandra L. Quittner, Kristen K. Marciel, Matthias Salathé, Anne E. O’Donnell, Mark H. Gotfried, Jonathan Ilowite, Mark L. Metersky, Patrick A. Flume, Sandra A. Lewis, Matthew McKevitt, A. Bruce Montgomery, Thomas G. O’Riordan, Alan F. Barker	2014	58
11	Pulmonary Complications of Intravenous Drug Abuse CHEST Journal ·Anne E. O’Donnell, Louis S. Pappas	1988	54
12	Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis Respirology ·Katherine O’Neill, Anne E. O’Donnell, Judy Bradley	2019	47
13	Pulmonary Complications Associated With Illicit Drug Use CHEST Journal ·Anne E. O’Donnell, Julie Selig, Manjari Aravamuthan, Michael Richardson	1995	35
14	The Prevalence and Significance of Staphylococcus aureus in Patients with Non–Cystic Fibrosis Bronchiectasis Annals of the American Thoracic Society ·Mark L. Metersky, Timothy R. Aksamit, Alan R. Barker, Radmila Choate, Charles L. Daley, M. Leigh Anne Daniels, Angela DiMango, Edward Eden, David E. Griffith, Margaret M. Johnson, Michael R. Knowles, Anne E. O’Donnell, Kenneth N. Olivier, Matthias Salathé, Byron Thomashow, Gregory Tino, Gerard Turino, Kevin Winthrop, David M. Mannino	2018	32
15	Exercise-induced Airflow Obstruction in a Healthy Military Population CHEST Journal ·Anne E. O’Donnell	1993	27
16	Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study European Respiratory Journal ·James D. Chalmers, Michal Shteinberg, Marcus Mall, Anne E. O’Donnell, Henrik Watz, Abhya Gupta, E. Frahm, Anastasia G Eleftheraki, J. Rauch, Sanjay H. Chotirmall, April Armstrong, Peter Eickholz, Naoki Hasegawa, Wiebke Sauter, Pamela J. McShane	2024	23
17	A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf ERJ Open Research ·James D. Chalmers, Abhya Gupta, Sanjay H. Chotirmall, April W. Armstrong, Peter Eickholz, Naoki Hasegawa, Pamela J. McShane, Anne E. O’Donnell, Michal Shteinberg, Henrik Watz, Anastasia G Eleftheraki, Claudia Diefenbach, Wiebke Sauter	2023	22
18	The Continuum of Care for Individuals With Lifelong Disabilities: Role of the Physical Therapist Physical Therapy ·Margo Orlin, Nancy Cicirello, Anne E. O’Donnell, Antonette Doty	2014	21
19	Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: An update Current Infectious Disease Reports ·Deepa G. Lazarous, Anne E. O’Donnell	2007	18
20	Bilateral Pyopneumothorax Secondary to Intravenous Drug Abuse CHEST Journal ·Thomas G. Zorc, Anne E. O’Donnell, Richard W. Holt, Louis S. Pappas, Joseph B. Slakey	1988	17

About Anne E. O’Donnell

Anne E. O’Donnell is a scholar working on Pulmonary and Respiratory Medicine, Emergency Medical Services, Speech and Hearing, Epidemiology and Transplantation, having authored 51 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cystic Fibrosis Research Advances (31 papers), Tracheal and airway disorders (17 papers), Neonatal Respiratory Health Research (15 papers), Pediatric health and respiratory diseases (7 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers), Dysphagia Assessment and Management (4 papers), Mycobacterium research and diagnosis (4 papers) and Tuberculosis Research and Epidemiology (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.5k citations), Speech and Hearing (213 citations), Emergency Medical Services (208 citations), Epidemiology (603 citations) and Infectious Diseases (197 citations). Anne E. O’Donnell has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Jonathan Ilowite, Alan F. Barker, Robert B. Fick, Armand Wolff, Mark L. Metersky, James D. Chalmers, Charles L. Daley, Matthias Salathé, Charles Haworth and Alan F. Barker. Their work appears in journals such as CHEST Journal, Clinics in Chest Medicine, Journal of Agricultural and Food Chemistry, The Lancet Respiratory Medicine and European Respiratory Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact